Cyclin-dependent kinase inhibitors for treating cancer

Medicinal Research Reviews

Volumn 21, Issue 6, 2001, Pages 487-498

  Toogood, Peter L ^a  

^a PFIZER INC   (United States)

Author keywords

Cdk4; Cyclin D; Kinase inhibitors

Indexed keywords

7 HYDROXYSTAUROSPORINE; AG 122275; AG 12275; ALSTERPAULLONE; CYCLIN D; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DANGGUI LONGHUI WAN; DIMETHYLAMINOPURINE; FLAVOPIRIDOL; INDIRUBIN; INDIRUBIN 3' MONOXIME; KENPAULLONE; N METHYL 4 [2 (2 OXOPYRIDO[2,3 E]INDOL 3 YLIDENE)HYDRAZINO]PHENYLMETHANESULFONAMIDE; N METHYL 4 [2 (7 OXOTHIAZOLO[4,5 E]INDOL 8 YLIDENE)HYDRAZINO]BENZENESULFONAMIDE; NSC 625987; OLOMOUCINE; OXINDOLE; PURINE DERIVATIVE; PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; ROSCOVITINE; RUBIDIUM ION; UNCLASSIFIED DRUG;

CANCER RESEARCH; CELL CYCLE G1 PHASE; CHINESE HERB; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; ENZYME INHIBITORS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 0034800665     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.1021     Document Type: Conference Paper

References (41)

1. Cancer cell cycles
2. The cell cycle: A review
3. Inhibitors of cyclin-dependent kinases as therapeutic agents for the treatment of cancer
4. Cyclins and cell cycle checkpoints
5. Control of the cell cycle and apoptosis
6. The cell cycle kinases
7. Cyclin-dependent protein kinases: Key regulators of the eukaryotic cell cycle
8. Cyclin-dependent kinases: Engines, clocks, and microprocessors
9. Induction of S phase by G1 regulatory factors
10. 1 cyclin-dependent kinases
11. The INK4 family of cell cycle inhibitors in cancer
12. 1-phase progression
13. Phosphorylation of E2F-1 by cyclin A-cdk2
14. Cell cycle. Fools rush in
15. Role of the retinoblastoma protein in the pathogenesis of human cancer
16. Inhibition of ras-induced proliferation and cellular transformation by p16INK4
17. Cell cycle arrest and inhibition of tumor cell proliferation by the p161NK4 gene mediated by an adenovirus vector
18. Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 may exert different inhibitory effects on cell growth and gene expression
19. Cyclin-dependent kinase inhibitors: Useful targets in cell cycle regulation
20. Novel drugs targeting the cell cycle
21. Targeting hyperproliferative disorders with cyclin dependent kinase inhibitors
22. ATP-site directed inhibitors of cyclin-dependent kinases
23. CDK inhibition and cancer therapy
24. Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: Current status
25. Flavopiridol binds to duplex DNA
26. UCN-01, 7-hydroxyl-staurosporine, inhibits kinase activity of cyclin-dependent kinases and reduces the phosphorylation of the retinoblastoma susceptibility gene product in A549 human lung cancer cell line
27. The chk1 protein kinase and the cdc25c regulatory pathways are targets of the anticancer agent UCN-01
28. 6-Dimethylaminopurine blocks starfish oocyte maturation by inhibiting a relevant protein kinase activity
29. Inhibition of cyclin-dependent kinases by purine derivatives
30. Inhibition of cyclin-dependent kinases by purine analogues. Crystal structure of human cdk2 complexed with roscovitine
31. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5
32. Exploiting chemical libraries, structure and genomics in the search for kinase inhibitors
33. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors
34. Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases
35. The paullones, a series of cyclin-dependent kinase inhibitors: Synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity
36. Indirubins inhibit glycogen synthase kinase-3β and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease - A property common to most CDK inhibitors?
37. Novel 2,4,6-triaminopyrimidine selectively inhibits cdk4/cyclin D1 activity in cancer cells
38. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4
39. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases
40. Cell cycle and biochemical effects of PD0183812; a potent inhibitor of cyclin-dependent kinase 4